DeepTek CXR Analyzer vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

DeepTek CXR Analyzer

by DeepTek

ElucidVivo A.3

by Elucid

AI Verdict

DeepTek CXR Analyzer is designed for broad chest X-ray analysis, assisting radiologists in detecting various lung, pleural, and cardiac pathologies. In contrast, ElucidVivo A.3 specializes in quantitative analysis of arterial plaque composition from CT angiography to aid in atherosclerosis patient stratification. While both are FDA-cleared AI tools in radiology and cardiology, they serve distinct diagnostic purposes and utilize different imaging modalities.

Choose DeepTek CXR Analyzer if…

Choose DeepTek CXR Analyzer if your primary need is to enhance the efficiency and accuracy of routine chest X-ray interpretation across a wide range of lung, pleural, and cardiac pathologies. This tool is ideal for high-volume environments where reducing radiologist workload and providing rapid, AI-assisted detection of suspicious regions is crucial for initial diagnostic support and workflow automation.

View DeepTek CXR Analyzer →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if your focus is on advanced, quantitative analysis of arterial plaque composition and stability from CT angiography for precise cardiovascular risk stratification. This system is best suited for cardiologists and vascular specialists requiring detailed insights into plaque characteristics, such as LRNC and calcifications, to optimize treatment decisions for atherosclerosis patients.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	DeepTek CXR Analyzer	ElucidVivo A.3
Pricing	Global access pricing available for eligible public sector and not-for-profit healthcare providers in 138 low- and middle-income countries, offering unlimited ai analyses per connected x-ray unit, installation, user training, product updates, maintenance, and technical support via an annual subscription.	Unknown
Deployment	On-premise and Cloud offerings. The solution supports online, offline, and hybrid deployment.	Cloud and on-premise secure deployment.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

DeepTek CXR Analyzer

DeepTek CXR Analyzer explicitly highlights 'seamless DICOM-based PACS integration' and claims to 'reduce radiologist workload by 30-50% and boost productivity by 2x-3x', directly addressing workflow efficiency and ease of use within existing clinical environments. While ElucidVivo A.3 offers advanced visualization features, Tool A's focus on integration and direct productivity gains provides a stronger case for overall usability.

Clinical Value

ElucidVivo A.3

Both tools are FDA-cleared and offer significant clinical benefits. However, ElucidVivo A.3 provides a deeper and more specific clinical insight through quantitative analysis of arterial plaque composition and stability, validated against histology, and the derivation of fractional flow reserve (FFRct). This enables advanced patient stratification and optimizes treatment decisions for atherosclerosis, offering a higher level of impact on patient management compared to DeepTek CXR Analyzer's broader CADe for chest X-rays.

Pricing & Value

DeepTek CXR Analyzer

DeepTek CXR Analyzer offers more transparency by stating a 'Pay-per-use' pricing model and providing flexibility as a 'technology offering or an AI-assisted reporting service'. This allows potential customers to better understand the cost structure and value proposition. ElucidVivo A.3 only states 'contact for pricing' without any further details on its pricing model.

Enterprise Readiness

DeepTek CXR Analyzer

DeepTek CXR Analyzer explicitly confirms HIPAA compliance, BAA availability, FDA clearance, and offers flexible deployment options (cloud and on-premise) with seamless PACS integration. ElucidVivo A.3's HIPAA compliance and BAA availability are only implied or not explicitly stated in the available information, which can be a significant hurdle for enterprise adoption where explicit compliance assurances are critical.

Innovation

ElucidVivo A.3

ElucidVivo A.3 demonstrates greater innovation by focusing on highly specialized, quantitative analysis of arterial plaque composition and stability, including histological validation and the derivation of FFRct. This provides predictive insights for personalized atherosclerosis management, moving beyond the more established Computer-Assisted Detection (CADe) applications seen in chest X-ray analysis offered by DeepTek CXR Analyzer.

Support & Docs

DeepTek CXR Analyzer

DeepTek CXR Analyzer indicates the availability of a 'Resources Hub' and 'Gateway Download & Installation Guide', and explicitly mentions '140+ Experts delivering 24x7 services' to '500+ Global Customers', suggesting robust support and documentation. In contrast, the available information for ElucidVivo A.3 does not explicitly detail its support services or publicly accessible documentation, with comparison sites often listing such details as 'Unknown' or 'Not specified'.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	DeepTek CXR Analyzer	ElucidVivo A.3
Tool Name	DeepTek CXR Analyzer	ElucidVivo A.3
Company	DeepTek Medical Imaging Pvt	Elucid Bioimaging
Primary Focus/Pathology	Chest X-ray analysis for lung, pleural, and cardiac pathologies	Quantitative analysis of arterial plaque composition and stability from CT angiography for atherosclerosis patient stratification
Key Analytical Output	Detection of 28 findings, automatic identification, categorization, and highlighting of suspicious regions of interest (ROIs), segregation of scans into 'AI Finding-Negative' and 'AI Finding-Positive'	Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications; derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity
Target Modality	Various X-ray modalities (hospital, mobile, portable, handheld)	CT angiography

Videos

Demos, reviews, and walkthroughs featuring DeepTek CXR Analyzer and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and what is the depth of their integration with our EHR/PACS systems?

DeepTek CXR Analyzer offers seamless DICOM-based PACS integration and generates secondary capture DICOMs with AI output for easy interpretation. ElucidVivo A.3 is designed to integrate with PACS/EMR systems, providing quantitative analysis directly within the imaging workflow.

What specific metrics or validation studies support the accuracy and sensitivity claims for detecting pathologies (DeepTek) or quantifying plaque characteristics (ElucidVivo)?

DeepTek CXR Analyzer is an FDA-cleared CADe solution for chest X-ray analysis, designed to significantly improve diagnostic accuracy by automatically detecting and highlighting suspicious regions. ElucidVivo A.3 provides quantitative analysis of arterial plaque composition and stability, with its measurements validated against ground-truth histology.

Given their distinct focuses, how do these tools specifically enhance diagnostic capabilities for different clinical specialties, such as pulmonology/radiology for DeepTek versus cardiology/vascular surgery for ElucidVivo?

DeepTek CXR Analyzer assists radiologists by automatically detecting and highlighting suspicious regions across lung, pleural, and cardiac pathologies on chest X-rays, reducing workload and boosting productivity. ElucidVivo A.3 provides detailed quantitative analysis of arterial plaque from CT angiography, aiding cardiologists, radiologists, and vascular surgeons in atherosclerosis patient stratification and optimizing treatment decisions.

What is the typical learning curve for physicians to become proficient with each tool, and what is the expected time-to-value in terms of improved efficiency or diagnostic confidence?

DeepTek CXR Analyzer aims to reduce radiologist workload by 30-50% and boost productivity by 2x-3x through its intelligent segregation and easy-to-interpret AI output, suggesting a rapid time-to-value. ElucidVivo A.3 offers detailed 3D visualizations and objective quantification of plaque characteristics, which, while powerful, would require familiarization with its specific analytical outputs for optimal utilization in patient stratification.

Can you provide information on the level of technical and clinical support offered, and are there opportunities to connect with existing customers for peer references?

Both companies are expected to offer comprehensive technical and clinical support to ensure smooth implementation and ongoing operation of their respective AI solutions. Information regarding customer reference sites and opportunities for peer-to-peer discussions can typically be provided upon request to help evaluate real-world impact and user experience.

What are the key considerations and support available for deploying these solutions across multiple clinical sites or hospital networks?

DeepTek CXR Analyzer offers both cloud and on-premise deployment options and is compatible with various X-ray modalities, facilitating multi-site rollouts. ElucidVivo A.3, as a software application, would also likely support flexible deployment models, and both vendors would typically provide implementation guidance and support for scaling across different locations and integrating with diverse IT infrastructures.